Table 1 Clinical and pathological characteristics of the adjuvant TACE and control groups

Age

53.8 ± 10.50

56.4 ± 11.7

0.21

Gender (male/female)

45/10

49/13

0.71

AFP level (ng/ml)

289.3 ± 406.1

171.8 ± 335.4

0.09

Child-Pugh class

5.21 ± 0.46

5.37 ± 0.73

0.18

 A

54

59

0.37

 B

1

3

Hepatitis B virus DNA value (10³ copies/ml)

294.9 ± 601.1

262.3 ± 1011.9

0.83

Surgical resection

0.99

 Hemihepatectomy

10

11

 Segment resection

31

35

 Wedge resection

14

16

Differentiation grade

0.88

 Well

10

13

 Middle

30

31

 Poor

15

18

1-week-after albumin levels (g/L)

36.4 ± 3.9

36.2 ± 4.1

0.85

Complications

14 (55)

21 (62)

0.321

Average length of stay (days)

12.5 ± 5.7

14.3 ± 5.4

0.08

Liver cirrhosis

47 (55)

53 (62)

0.99

Maximum tumor diameter (cm)

4.9 ± 3.5

5.0 ± 3.1

0.96

 >5 cm

17

24

0.34

 ≤5 cm

38

38

Tumor encapsulation

36 (55)

38 (62)

0.64

Presence of satellite nodules

17 (55)

20 (62)

0.88

Microvascular invasion

24 (55)

26 (62)

0.85

Preemptive lamivudine therapy

18 (55)

22 (62)

0.75